Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.

Circulation. Cardiovascular interventions - 1 Oct 2011

Hulot Jean-Sébastien, Collet Jean-Philippe, Cayla Guillaume, Silvain Johanne, Allanic Frédérick, Bellemain-Appaix Anne, Scott Stuart A, Montalescot Gilles

Abstract excerpt

BACKGROUND: Reduced concentrations of clopidogrel active metabolite have been associated with diminished platelet inhibition and higher rates of adverse cardiovascular events. Paraoxonase-1 (PON1) has recently been proposed as a key enzyme for clopidogrel metabolic activation. We tested the effects of PON1 polymorphisms on clopidogrel pharmacokinetics and pharmacodynamics and the occurrence of cardiovascular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryldialkylphosphatase
Share to Biomarkers, Pharmacological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clopidogrel

Share to Cross-Over Studies

Share to Cytochrome P-450 CYP2C19

Share to Platelet Aggregation Inhibitors

Share to Platelet Function Tests

Share to Ticlopidine

Source

Identifiers

PMID: 21972404
DOI: 10.1161/CIRCINTERVENTIONS.111.963025

Genes

PON1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.PMID 21972404Read ↗

Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention.Semantic proximity Read ↗

Genetic and nongenetic factors influencing the response to clopidogrel.Semantic proximity Read ↗

CYP2C19 and effect of clopidogrel for secondary prevention of major ischemic events: systematic review and meta-analysisSemantic proximity Read ↗

Pharmacogenomics of clopidogrel: evidence and perspectives.Semantic proximity Read ↗

Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response.Semantic proximity Read ↗

Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement.Semantic proximity Read ↗

Paraoxonase-1 is a major determinant of clopidogrel efficacy.Semantic proximity Read ↗

Clopidogrel PharmacogeneticsSemantic proximity Read ↗

Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction.Semantic proximity Read ↗

The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention.Semantic proximity Read ↗

Genetic variation in activating clopidogrel: longer-term outcomes in a large community cohortSemantic proximity Read ↗

Clinical Outcomes after Percutaneous Coronary Intervention Over Time on the Basis of CYP2C19 Polymorphisms: Evidence from a Chinese CohortSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.